Medical - Diagnostics & Research
Build Your Comparison
Side-by-side financial analysisStock Comparison
BLLN vs EXAS vs KO
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
Beverages - Non-Alcoholic
BLLN vs EXAS vs KO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||
|---|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Beverages - Non-Alcoholic |
| Market Cap | $4.65B | $20.02B | $355.61B |
| Revenue (TTM) | $355M | $3.25B | $49.28B |
| Net Income (TTM) | $25M | $-208M | $13.70B |
| Gross Margin | 70.4% | 69.7% | 61.7% |
| Operating Margin | 10.2% | -6.4% | 29.3% |
| Forward P/E | 102.7x | 582.8x | 25.3x |
| Total Debt | $109M | $2.52B | $45.49B |
| Cash & Equiv. | $496M | $956M | $10.27B |
BLLN vs EXAS vs KO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | Mar 26 | Return |
|---|---|---|---|
| Exact Sciences Corp… (EXAS) | 100 | 120.7 | +20.7% |
| The Coca-Cola Compa… (KO) | 100 | 182.5 | +82.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BLLN vs EXAS vs KO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BLLN is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth 100.0%, EPS growth 106.8%
- Lower volatility, beta 1.91, Low D/E 22.7%, current ratio 11.69x
- Beta 1.91, current ratio 11.69x
EXAS is the clearest fit if your priority is momentum.
- +94.2% vs BLLN's -7.2%
KO carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 121.1% 10Y total return vs EXAS's 13.9%
- Lower P/E (25.3x vs 102.7x)
- 27.8% margin vs EXAS's -6.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 100.0% revenue growth vs KO's 1.9% | |
| Value | Lower P/E (25.3x vs 102.7x) | |
| Quality / Margins | 27.8% margin vs EXAS's -6.4% | |
| Stability / Safety | Lower D/E ratio (22.7% vs 132.7%) | |
| Dividends | 2.5% yield; 56-year raise streak; the other 2 pay no meaningful dividend | |
| Momentum (1Y) | +94.2% vs BLLN's -7.2% | |
| Efficiency (ROA) | 13.1% ROA vs EXAS's -3.5%, ROIC 15.8% vs -3.6% |
BLLN vs EXAS vs KO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
BLLN vs EXAS vs KO — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Evenly matched — BLLN and KO each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
KO is the larger business by revenue, generating $49.3B annually — 139.0x BLLN's $355M. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to EXAS's -6.4%. On growth, BLLN holds the edge at +83.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||
|---|---|---|---|
| RevenueTrailing 12 months | $355M | $3.2B | $49.3B |
| EBITDAEarnings before interest/tax | $44M | -$41M | $15.5B |
| Net IncomeAfter-tax profit | $25M | -$208M | $13.7B |
| Free Cash FlowCash after capex | $28M | $357M | $12.6B |
| Gross MarginGross profit ÷ Revenue | +70.4% | +69.7% | +61.7% |
| Operating MarginEBIT ÷ Revenue | +10.2% | -6.4% | +29.3% |
| Net MarginNet income ÷ Revenue | +7.1% | -6.4% | +27.8% |
| FCF MarginFCF ÷ Revenue | +7.9% | +11.0% | +25.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +83.8% | +23.1% | +12.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +4.8% | +90.4% | +18.2% |
Valuation Metrics
EXAS leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 27.2x trailing earnings, KO trades at a 98% valuation discount to BLLN's 1587.4x P/E. On an enterprise value basis, KO's 26.4x EV/EBITDA is more attractive than BLLN's 266.1x.
| Metric | |||
|---|---|---|---|
| Market CapShares × price | $4.7B | $20.0B | $355.6B |
| Enterprise ValueMkt cap + debt − cash | $4.3B | $21.6B | $390.8B |
| Trailing P/EPrice ÷ TTM EPS | 1587.44x | -95.37x | 27.18x |
| Forward P/EPrice ÷ next-FY EPS est. | 102.72x | 582.83x | 25.27x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 2.43x |
| EV / EBITDAEnterprise value multiple | 266.12x | — | 26.39x |
| Price / SalesMarket cap ÷ Revenue | 15.24x | 6.16x | 7.42x |
| Price / BookPrice ÷ Book value/share | 9.65x | 8.24x | 10.40x |
| Price / FCFMarket cap ÷ FCF | 295.98x | 56.10x | 67.15x |
Profitability & Efficiency
Evenly matched — BLLN and KO each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-9 for EXAS. BLLN carries lower financial leverage with a 0.23x debt-to-equity ratio, signaling a more conservative balance sheet compared to KO's 1.33x.
| Metric | |||
|---|---|---|---|
| ROE (TTM)Return on equity | +7.6% | -8.7% | +41.1% |
| ROA (TTM)Return on assets | +5.1% | -3.5% | +13.1% |
| ROICReturn on invested capital | +13.5% | -3.6% | +15.8% |
| ROCEReturn on capital employed | +3.7% | -4.0% | +17.3% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 7 | 7 |
| Debt / EquityFinancial leverage | 0.23x | 1.05x | 1.33x |
| Net DebtTotal debt minus cash | -$387M | $1.6B | $35.2B |
| Cash & Equiv.Liquid assets | $496M | $956M | $10.3B |
| Total DebtShort + long-term debt | $109M | $2.5B | $45.5B |
| Interest CoverageEBIT ÷ Interest expense | 516.43x | -5.47x | 10.70x |
Total Returns (Dividends Reinvested)
KO leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KO five years ago would be worth $16,560 today (with dividends reinvested), compared to $8,392 for EXAS. Over the past 12 months, EXAS leads with a +94.2% total return vs BLLN's -7.2%. The 3-year compound annual growth rate (CAGR) favors KO at 13.7% vs BLLN's -2.5% — a key indicator of consistent wealth creation.
| Metric | |||
|---|---|---|---|
| YTD ReturnYear-to-date | +13.2% | +3.1% | +20.3% |
| 1-Year ReturnPast 12 months | -7.2% | +94.2% | +17.2% |
| 3-Year ReturnCumulative with dividends | -7.2% | +15.2% | +47.0% |
| 5-Year ReturnCumulative with dividends | -7.2% | -16.1% | +65.6% |
| 10-Year ReturnCumulative with dividends | -7.2% | +1390.2% | +121.1% |
| CAGR (3Y)Annualised 3-year return | -2.5% | +4.8% | +13.7% |
Risk & Volatility
Evenly matched — EXAS and KO each lead in 1 of 2 comparable metrics.
Risk & Volatility
KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than BLLN's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EXAS currently trades 99.9% from its 52-week high vs BLLN's 72.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.91x | -0.05x | -0.20x |
| 52-Week HighHighest price in past year | $138.70 | $104.98 | $84.04 |
| 52-Week LowLowest price in past year | $61.96 | $38.81 | $65.35 |
| % of 52W HighCurrent price vs 52-week peak | +72.9% | +99.9% | +98.3% |
| RSI (14)Momentum oscillator 0–100 | 56.5 | 76.4 | 60.6 |
| Avg Volume (50D)Average daily shares traded | 642K | 21.6M | 12.7M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: BLLN as "Buy", EXAS as "Buy", KO as "Buy". Consensus price targets imply 23.6% upside for BLLN (target: $125) vs 0.1% for EXAS (target: $105). KO is the only dividend payer here at 2.46% yield — a key consideration for income-focused portfolios.
| Metric | |||
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $125.00 | $105.00 | $86.13 |
| # AnalystsCovering analysts | 4 | 41 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | — | +2.5% |
| Dividend StreakConsecutive years of raises | — | — | 56 |
| Dividend / ShareAnnual DPS | — | — | $2.04 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.1% | +0.2% |
EXAS leads in 1 of 6 categories (Valuation Metrics). KO leads in 1 (Total Returns). 3 tied.
BLLN vs EXAS vs KO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is BLLN or EXAS or KO a better buy right now?
For growth investors, BillionToOne, Inc.
(BLLN) is the stronger pick with 100. 0% revenue growth year-over-year, versus 1. 9% for The Coca-Cola Company (KO). The Coca-Cola Company (KO) offers the better valuation at 27. 2x trailing P/E (25. 3x forward), making it the more compelling value choice. Analysts rate BillionToOne, Inc. (BLLN) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BLLN or EXAS or KO?
On trailing P/E, The Coca-Cola Company (KO) is the cheapest at 27.
2x versus BillionToOne, Inc. at 1587. 4x. On forward P/E, The Coca-Cola Company is actually cheaper at 25. 3x.
03Which is the better long-term investment — BLLN or EXAS or KO?
Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.
6%, compared to -16. 1% for Exact Sciences Corporation (EXAS). Over 10 years, the gap is even starker: EXAS returned +1390% versus BLLN's -7. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BLLN or EXAS or KO?
By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.
20β versus BillionToOne, Inc. 's 1. 91β — meaning BLLN is approximately -1053% more volatile than KO relative to the S&P 500. On balance sheet safety, BillionToOne, Inc. (BLLN) carries a lower debt/equity ratio of 23% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.
05Which is growing faster — BLLN or EXAS or KO?
By revenue growth (latest reported year), BillionToOne, Inc.
(BLLN) is pulling ahead at 100. 0% versus 1. 9% for The Coca-Cola Company (KO). On earnings-per-share growth, the picture is similar: BillionToOne, Inc. grew EPS 106. 8% year-over-year, compared to 23. 6% for The Coca-Cola Company. Over a 3-year CAGR, EXAS leads at 15. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — BLLN or EXAS or KO?
The Coca-Cola Company (KO) is the more profitable company, earning 27.
3% net margin versus -6. 4% for Exact Sciences Corporation — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -6. 4% for EXAS. At the gross margin level — before operating expenses — EXAS leads at 69. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is BLLN or EXAS or KO more undervalued right now?
On forward earnings alone, The Coca-Cola Company (KO) trades at 25.
3x forward P/E versus 582. 8x for Exact Sciences Corporation — 557. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BLLN: 23. 6% to $125. 00.
08Which pays a better dividend — BLLN or EXAS or KO?
In this comparison, KO (2.
5% yield) pays a dividend. BLLN, EXAS do not pay a meaningful dividend and should not be held primarily for income.
09Is BLLN or EXAS or KO better for a retirement portfolio?
For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
05), +1390% 10Y return). BillionToOne, Inc. (BLLN) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXAS: +1390%, BLLN: -7. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between BLLN and EXAS and KO?
These companies operate in different sectors (BLLN (Healthcare) and EXAS (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: BLLN is a small-cap high-growth stock; EXAS is a mid-cap high-growth stock; KO is a large-cap quality compounder stock. KO pays a dividend while BLLN, EXAS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.